In the GLP-1 RA group, 33 participants were subsequently newly diagnosed with heart failure, compared with 15 in the SGLT2i group (RR 0.44 [95% CI 0.23, 0.83] p =0.0092)
Overall, the totality of the preclinical data we have generated in the obesity space demonstrating the successful delivery of both single and triagonist incretin therapies gives us confidence to continue building our obesity portfolio to unlock the true value of the RaniPill technology
Different Dual Approaches# Weight Loss Comparison# Cross-trial comparison is limited by differences in population, duration, dose escalation, and trial design
How GLP-1 ID Supports Side Effect Management GLP-1 ID combines customized care, flexible medication options, and ongoing support
View Source ORTHOP J SPORTS MED BPC-157 in Orthopaedic Sports Medicine Systematic Review 2025 Vasireddi N, Hahamyan H, Salata MJ, et al
VITAstir is my go to for B12 which I need for my Pernicious Anemia treatment